The Food and Drug Administration (FDA) has given its first approval to a drug for spinal muscular atrophy, a hereditary disease that causes weakness and muscle wasting. The drug, Spinraza (nusinersen), is an antisense oligonucleotide that binds to RNA in order to regulate gene expression.
